Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells."

26 Mar 2024

Vitamin D shows promise in targeting aging's biological mechanisms, study finds

What is currently known about the potential effect of vitamin D (VitD) on modulating some hallmarks of aging.

26 Mar 2024

Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant

Among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid leukemia (AML) between 2000 and 2021, leukemia-free and overall survival improved significantly over time.

22 Mar 2024

Groundbreaking atlas maps over 80 blood stem cell types

Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

21 Mar 2024

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.

21 Mar 2024

NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia

Scientists from the National University of Singapore (NUS) have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukaemia (AML), a type of aggressive blood cancer.

19 Mar 2024

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

A new study published in Nature explores the safety and benefits of this diet in adults with cancer, in addition to its feasibility in this population.

15 Mar 2024

Innovative therapy targets and destroys leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells.

26 Feb 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

St. Jude Children's Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

12 Feb 2024

Proteogenomics provides clues about drug response in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

6 Feb 2024

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

2 Feb 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 29 Jan 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

12 Jan 2024

Hidden identity of blood cancer revealed

Leukemia is a common term used to refer to a form of blood cancer. However, there are different types of leukemia depending on the cell type involved.

9 Jan 2024

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

28 Dec 2023

Survival rates of black patients with leukemia soar with modern therapies

Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

11 Dec 2023

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

Acute Myeloid Leukemia News and Research

Further Reading

ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

Vitamin D shows promise in targeting aging's biological mechanisms, study finds

Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant

Groundbreaking atlas maps over 80 blood stem cell types

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

Innovative therapy targets and destroys leukemia stem cells

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

Proteogenomics provides clues about drug response in acute myeloid leukemia

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

Hidden identity of blood cancer revealed

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

Survival rates of black patients with leukemia soar with modern therapies

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

New combinations and targeted therapies for acute myeloid leukemia on the horizon

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News